B7-H3 Chimeric Antigen Receptor Redirected T Cells Target Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma

B7-H3 Chimeric Antigen Receptor Redirected T Cells Target Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma

Potent CAR-T therapies that target appropriate antigens can benefit the treatment of anaplastic lymphoma kinase-positive (ALK<sup>+</sup>) anaplastic large cell lymphoma (ALCL), which is the most common subtype of T cell lymphoma. In this study, we observed overexpression of B7-H3 in ALC...

Full description

Bibliographic Details
Main Authors:	Zhenguo Zi, Haihong Zhao, Huanyu Wang, Xiaojing Ma, Fang Wei
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Cancers
Subjects:	ALCL ALK B7-H3 CAR-T
Online Access:	https://www.mdpi.com/2072-6694/12/12/3815

Similar Items

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
by: Suzanne D. Turner
Published: (2017-10-01)

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
by: Michael T. Werner, et al.
Published: (2017-10-01)

Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma—Experience from an Indian Center
by: Muthiah Vaikundaraja Indhuja, et al.

A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation
by: Kazunori Kawasoe, et al.
Published: (2023-10-01)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
by: Yuan Wang, et al.
Published: (2022-02-01)

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma
by: Giulia Arosio, et al.
Published: (2021-09-01)

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin
by: Ritsuko Nakai, et al.
Published: (2019-12-01)

Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment
by: Xin-Rui Zhang, et al.
Published: (2022-03-01)

The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
by: Ivonne A. Montes-Mojarro, et al.
Published: (2018-04-01)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
by: Serena Stadler, et al.
Published: (2018-04-01)

BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
by: Gavin D. Garland, et al.
Published: (2021-12-01)

Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
by: Camille Daugrois, et al.
Published: (2021-11-01)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
by: Vijay Kumar Singh, et al.
Published: (2019-09-01)

Uncommon spinal involvement of ALK-positive anaplastic large cell lymphoma: A pediatric case report and literature review
by: Mohammed Al amine El farissi, et al.
Published: (2024-01-01)

Cardiac anaplastic large cell lymphoma in an 8-year old boy
by: Melchior Lauten, et al.
Published: (2014-01-01)

Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma
by: Beatrice Belmonte, et al.
Published: (2021-06-01)

ALK signaling and target therapy in anaplastic large cell lymphoma
by: Fabrizio eTabbo, et al.
Published: (2012-05-01)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
by: Takashi Onaka, et al.
Published: (2018-05-01)

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BI-ALCL)
by: R. Sabetta, et al.
Published: (2020-03-01)

Extreme Hypoglycaemia in Anaplastic Large Cell Lymphoma
by: Lidor Akavia, et al.
Published: (2017-03-01)

Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent
by: Chuquan Shang, et al.
Published: (2021-01-01)

Updates in pathobiological aspects of anaplastic large cell lymphoma
by: Rui Wu, et al.
Published: (2023-09-01)

Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review
by: Kazuhiro Noguchi, et al.
Published: (2023-12-01)

Breast Implant and Anaplastic Large Cell Lymphoma Meta-Analysis
by: Guillermo Ramos-Gallardo, et al.
Published: (2017-01-01)

Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse
by: Christopher N. Nguyen, BA, et al.
Published: (2021-11-01)

PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma
by: I. Garces de los Fayos Alonso, et al.
Published: (2022-08-01)

Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
by: Nina Prokoph, et al.
Published: (2018-03-01)

Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer
by: Peng SONG, et al.
Published: (2018-09-01)

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
by: Kazuhiro Noguchi, et al.
Published: (2023-02-01)

Anaplastic large cell lymphoma of breast masquerading suppurative mastitis on cytology
by: Sailuja Maharjan, et al.
Published: (2022-08-01)

Role and targeting of anaplastic lymphoma kinase in cancer
by: Carminia Maria Della Corte, et al.
Published: (2018-02-01)

Current Progress in Breast Implant-Associated Anaplastic Large Cell Lymphoma
by: Yichen Wang, et al.
Published: (2022-01-01)

Comprehensive Evaluation of the Current Knowledge on Breast Implant Associated-Anaplastic Large Cell Lymphoma
by: Hyokyung Yoo, et al.
Published: (2022-03-01)

Anaplastic large cell lymphoma: A great mimic on cytology
by: Mona A Agnihotri, et al.
Published: (2017-01-01)

Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2014-12-01)

Primary anaplastic large T-cell lymphoma of the psoas muscle
by: Irene Pecorella, et al.
Published: (2021-05-01)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
by: Jennifer E. Agrusa, et al.
Published: (2023-05-01)

Effect of bevacizumab on brain radiation necrosis in anaplastic lymphoma kinase‐positive lung cancer
by: Kengo Tanigawa, et al.
Published: (2019-10-01)

18F-FDG PET/CT imaging findings in anaplastic large cell lymphoma, a rare subtype of lymphoma
by: Yanping Jiang, et al.
Published: (2020-01-01)

Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review
by: Fabien Moinard-Butot, et al.
Published: (2023-10-01)